Tableaux de Dose Calculateur Mélanges & Stacks Apprendre Blog Peptides Approbations
Ouvrir le Calculateur
PeptideDosageCharts  ›  Approbations

Preuves et Statut d'Approbation

Tous les peptides que nous couvrons, classés selon les preuves réelles — des médicaments approuvés par les régulateurs (FDA, EMA, MHRA, TGA) aux composés en phase clinique et préclinique. Vérifié auprès des régulateurs et de la littérature évaluée par les pairs.

Composé Catégorie Niveau de preuve Approuvé par Base / marque
Tesamorelin Egrifta Growth Hormone Approuvé FDA Egrifta — FDA 2010, HIV-associated lipodystrophy
HCG Human Chorionic Gonadotropin Hormonal Approuvé FDA EMA Pregnyl/Novarel/Ovidrel — FDA, fertility & hypogonadism
Oxytocin Hormonal Approuvé FDA EMA MHRA TGA Pitocin/Syntocinon — FDA, labor induction & PPH
SS-31 Elamipretide Mitochondrial Approuvé FDA Forzinity (elamipretide) — FDA Sep 2025, Barth syndrome
HGH 191AA Somatropin Growth Hormone Approuvé FDA EMA MHRA TGA Somatropin (Genotropin/Norditropin) — FDA/EMA, GH deficiency
Tirzepatide Mounjaro / LY3298176 GLP-1 / Metabolic Approuvé FDA EMA MHRA TGA Mounjaro/Zepbound — FDA 2022, T2D, obesity & OSA
Gonadorelin GnRH Hormonal Approuvé FDA Factrel — FDA, GnRH for pituitary testing (discontinued)
Sermorelin Growth Hormone Approuvé FDA Geref — FDA 1997 (discontinued 2008), pediatric GH deficiency
Melanotan I Afamelanotide Other Approuvé FDA EMA TGA Scenesse (afamelanotide) — FDA 2019/EMA 2015, erythropoietic protoporphyria
PT-141 Bremelanotide Other Approuvé FDA Vyleesi (bremelanotide) — FDA 2019, HSDD
Semaglutide Ozempic / Wegovy GLP-1 / Metabolic Approuvé FDA EMA MHRA TGA Ozempic/Wegovy/Rybelsus — FDA 2017, diabetes & obesity
GHRP-2 Growth Hormone Approuvé PMDA Pralmorelin (GHRP Kaken) — PMDA Japan, GH-deficiency diagnostic
Liraglutide Victoza / Saxenda GLP-1 / Metabolic Approuvé FDA EMA MHRA TGA Victoza/Saxenda — FDA/EMA, T2D & obesity
VIP Vasoactive Intestinal Peptide Other Approuvé MHRA As Invicorp (VIP+phentolamine) — MHRA UK 2000, erectile dysfunction
Dulaglutide Trulicity GLP-1 / Metabolic Approuvé FDA EMA Trulicity — FDA & EMA 2014, type 2 diabetes
Pentosan Polysulfate PPS Healing & Recovery Approuvé FDA EMA TGA Elmiron — FDA 1996, interstitial cystitis
Orforglipron LY3502970 GLP-1 / Metabolic Approuvé FDA Foundayo — FDA Apr 2026, oral GLP-1 for chronic weight management
Tirzepatide 15mg Mounjaro GLP-1 / Metabolic Approuvé FDA EMA MHRA TGA Mounjaro 15mg — FDA/EMA, highest maintenance dose
Amlexanox Metabolic Approuvé FDA Aphthasol — FDA 1997, aphthous ulcers (US-discontinued)
Exenatide Byetta / Bydureon GLP-1 / Metabolic Approuvé FDA EMA Byetta/Bydureon — FDA 2005, type 2 diabetes
Pramlintide Symlin GLP-1 / Metabolic Approuvé FDA Symlin — FDA 2005, amylin analog adjunct to insulin
IGF-1 (IGtropin) IGF-1 Growth Factor Approuvé FDA EMA As Mecasermin (Increlex) — FDA/EMA, severe primary IGF-1 deficiency
Setmelanotide Imcivree Metabolic Approuvé FDA EMA Imcivree — FDA 2020/EMA, monogenic & hypothalamic obesity
Lixisenatide Adlyxin GLP-1 / Metabolic Approuvé FDA EMA TGA Adlyxin/Lyxumia — FDA/EMA, type 2 diabetes
ACTH 1-39 Corticotropin, full-length ACTH Hormonal Approuvé FDA as corticotropin (H.P. Acthar Gel)
Triptorelin Triptorelin Acetate, Trelstar, Decapeptyl Hormonal Approuvé FDA EMA GnRH agonist (Trelstar/Decapeptyl)
Noopept Cognitive Approuvé (intl) ROSZ Russia (ROSZ) — vascular/traumatic cognitive disorders
Cerebrolysin Cognitive Approuvé (intl) INTL National approval Austria (EU) + 50+ countries; not FDA/EMA-central
Selank Cognitive Approuvé (intl) ROSZ Russia (ROSZ) — prescription anxiolytic
Semax Cognitive Approuvé (intl) ROSZ Russia (ROSZ) — ischemic stroke & cognitive disorders
Thymosin Alpha-1 Zadaxin Immune Approuvé (intl) NMPA Zadaxin — Italy (EU) + China + 35 countries; not FDA/EMA-central
Mazdutide IBI362 / LY3305677 GLP-1 / Metabolic Approuvé (intl) NMPA China NMPA 2025 — GCG/GLP-1 agonist for obesity & T2D
Thymalin Immune Approuvé (intl) ROSZ Russia (ROSZ) since 1982 — immunomodulator
Thymogen Glutamyl-Tryptophan Immune Approuvé (intl) ROSZ Russia (ROSZ) — Glu-Trp immunostimulant
BPC-157 Body Protection Compound 157 Healing & Recovery Preuves cliniques Non approuvé Small pilot human studies exist; unapproved, FDA Category 2 (barred from compounding).
GHK-Cu Copper Peptide Skin & Repair Preuves cliniques Non approuvé Human topical skin/wound/hair studies; cosmetic ingredient, not an approved drug.
Glutathione GSH Longevity Preuves cliniques Non approuvé Antioxidant sold as a supplement; human IV/oral trials exist, no drug approval as GSH.
NAD+ Nicotinamide adenine dinucleotide Longevity Preuves cliniques Non approuvé Endogenous coenzyme sold as a supplement; human trials exist, not a drug.
NMN Nicotinamide Mononucleotide Longevity Preuves cliniques Non approuvé Dietary supplement (FDA: not a drug) with multiple human RCTs on NAD+ raising.
MK-677 Ibutamoren Growth Hormone Preuves cliniques Non approuvé Oral GH secretagogue completed multiple Phase 2/3 trials; never submitted/approved.
Retatrutide LY3437943 GLP-1 / Metabolic Preuves cliniques Non approuvé Investigational triple agonist in Phase 3 obesity trials; not yet approved.
Spermidine Longevity Preuves cliniques Non approuvé Dietary polyamine with human RCTs (mixed); sold as a supplement, not a drug.
Melanotan II MT-II Other Preuves cliniques Non approuvé Unapproved melanocortin agonist with small human trials; precursor to bremelanotide.
Ipamorelin Growth Hormone Preuves cliniques Non approuvé Selective GH secretagogue reached early-phase human trials; never approved.
SNAP-8 Skin & Repair Preuves cliniques Non approuvé Topical cosmetic octapeptide with human in-vivo wrinkle studies; not a drug.
AOD-9604 Metabolic Preuves cliniques Non approuvé Multiple human obesity trials (Phase 2b) that failed efficacy; food-ingredient GRAS only.
Argireline Acetyl Hexapeptide-8 Skin & Repair Preuves cliniques Non approuvé Cosmetic peptide with published human topical wrinkle studies; not a drug.
DSIP Delta Sleep-Inducing Peptide Sleep Preuves cliniques Non approuvé Small human sleep/pain pilot trials with mixed results; never approved.
Epitalon Epithalon Longevity Preuves cliniques Non approuvé Russian human clinical observations (Khavinson); no Western approval.
Thymosin Beta-4 TB4 Healing & Recovery Preuves cliniques Non approuvé Full-length Tβ4 (RGN-259) tested in Phase 2/3 (dry eye/keratopathy); not approved.
CJC-1295 DAC Growth Hormone Preuves cliniques Non approuvé Long-acting GHRH analog reached Phase 1/2 (ConjuChem); discontinued.
Follistatin 344 Growth Factor Preuves cliniques Non approuvé AAV1-FS344 follistatin gene therapy reached Phase 1/2a; not commercial.
GHRP-6 Growth Hormone Preuves cliniques Non approuvé GH-releasing hexapeptide studied in humans for GH secretion; not approved.
Kisspeptin Hormonal Preuves cliniques Non approuvé Reproductive-hormone peptide studied in many human trials; not approved.
LL-37 Immune Preuves cliniques Non approuvé Human cathelicidin investigated in early human wound/ulcer studies; not approved.
Matrixyl Palmitoyl Pentapeptide-4 Skin & Repair Preuves cliniques Non approuvé Cosmetic anti-aging peptide with published human skin studies; not a drug.
Cagrilintide GLP-1 / Metabolic Preuves cliniques Non approuvé Novo amylin analog in Phase 3 (CagriSema); not yet approved.
Tesofensine Metabolic Preuves cliniques Non approuvé Triple monoamine reuptake inhibitor in Phase 3 for obesity; not approved.
Retatrutide 12mg LY3437943 GLP-1 / Metabolic Preuves cliniques Non approuvé Same investigational molecule (12mg dose), Phase 3; not approved.
Hexarelin Growth Hormone Preuves cliniques Non approuvé Same molecule as Examorelin; Phase 2, never marketed.
Survodutide BI 456906 GLP-1 / Metabolic Preuves cliniques Non approuvé GLP-1/glucagon dual agonist in Phase 3 (obesity, MASH); FDA Breakthrough, not approved.
Adipotide FTPP Metabolic Preuves cliniques Non approuvé Reached a Phase 1 oncology trial, terminated for nephrotoxicity.
Copper Tripeptide-1 GHK-Cu variant Skin & Repair Preuves cliniques Non approuvé GHK-Cu has human topical wound/skin studies; cosmetic ingredient, not a drug.
ACE-031 Growth Factor Preuves cliniques Non approuvé Myostatin trap reached randomized Phase 2 (DMD), halted 2011 for safety.
Larazotide Gastrointestinal Preuves cliniques Non approuvé Zonulin antagonist completed Phase 3 (celiac); failed endpoint, not approved.
ARA-290 Cibinetide Healing & Recovery Preuves cliniques Non approuvé EPO-derived peptide, Phase 2 in sarcoidosis neuropathy; no marketing approval.
Follistatin 315 Growth Factor Preuves cliniques Non approuvé Delivered via AAV1-FS344 gene therapy in Phase 1/2a muscular dystrophy trials.
GHRP-1 Growth Hormone Preuves cliniques Non approuvé Synthetic GH secretagogue tested in human GH-release studies; never approved.
Examorelin Hexarelin Growth Hormone Preuves cliniques Non approuvé Hexarelin; reached Phase 2 (GHD, heart failure) but never marketed.
Vesugen Bioregulator Preuves cliniques Non approuvé Khavinson vascular tripeptide with small non-controlled Russian human studies.
Vilon Bioregulator Preuves cliniques Non approuvé Khavinson Lys-Glu dipeptide with small Russian immunogerontology human studies.
FGL FG Loop peptide Cognitive Preuves cliniques Non approuvé NCAM-mimetic completed a Phase 1 intranasal safety study; not approved.
Testagen Bioregulator Preuves cliniques Non approuvé Khavinson testis bioregulator with one small unreplicated Russian human study.
TB-500 Thymosin Beta-4 fragment Healing & Recovery Préclinique Non approuvé Synthetic Tβ4 fragment with animal/in-vitro data only; no human trials of the fragment.
MOTS-c Metabolic Préclinique Non approuvé Mitochondrial-derived peptide with extensive preclinical data; no controlled human therapeutic trials.
SLU-PP-332 Metabolic Préclinique Non approuvé Pan-ERR agonist exercise-mimetic studied in mice/in-vitro only.
KPV Lysine-Proline-Valine Anti-inflammatory Préclinique Non approuvé Anti-inflammatory α-MSH fragment with animal/in-vitro evidence only.
5-Amino-1MQ Metabolic Préclinique Non approuvé NNMT inhibitor — mouse/in-vitro obesity data only; no human trials.
IGF-1 LR3 Growth Factor Préclinique Non approuvé Long-acting IGF-1 analog research reagent; no human trials.
CJC-1295 (no DAC) Mod GRF 1-29 Growth Hormone Préclinique Non approuvé Short-acting GHRH analog; no dedicated published human trials.
HGH Fragment 176-191 AOD precursor Metabolic Préclinique Non approuvé Unmodified fragment has no human trials; only the modified AOD-9604 was tested in humans.
MGF Mechano Growth Factor Growth Factor Préclinique Non approuvé IGF-1 splice variant with animal/in-vitro evidence only.
FOXO4-DRI Longevity Préclinique Non approuvé Senolytic peptide studied in cell-culture and mice only.
Dihexa Cognitive Préclinique Non approuvé Angiotensin-IV-derived cognitive peptide; animal/in-vitro only.
N-Acetyl Semax NA-Semax Cognitive Préclinique Non approuvé Acetylated research analog of Semax; the analog itself lacks human trials.
PEG-MGF Growth Factor Préclinique Non approuvé Pegylated IGF-1 splice variant; no published human trials.
PNC-27 Other Préclinique Non approuvé p53-derived anti-cancer peptide tested in cell lines/animals only.
Humanin Longevity Préclinique Non approuvé Studied in vitro/animals + observational plasma data; no interventional human trial.
IGF-1 DES DES(1-3) IGF-1 Growth Factor Préclinique Non approuvé Truncated IGF-1 analog used in preclinical research only.
GDF-11 Longevity Préclinique Non approuvé Animal/in-vitro therapeutic studies + observational biomarker data; no interventional human trials.
N-Acetyl Selank NA-Selank Cognitive Préclinique Non approuvé Stabilized research analog of Selank; the analog itself lacks human trials.
Ovagen Bioregulator Préclinique Non approuvé Khavinson tripeptide (supplement); animal/in-vitro, no controlled human trials.
Cortagen Bioregulator Préclinique Non approuvé Khavinson cortex bioregulator (supplement); preclinical only.
P21 P021 Cognitive Préclinique Non approuvé CNTF-mimetic neurogenic peptide with animal/in-vitro data only.
Pinealon Bioregulator Préclinique Non approuvé Khavinson tripeptide (supplement); in-vitro/rodent data only.
Prostamax Bioregulator Préclinique Non approuvé Khavinson tetrapeptide studied in rat/in-vitro models; no drug approval.
B7-33 Other Préclinique Non approuvé Relaxin mimetic with rodent/in-vitro anti-fibrotic data only.
Livagen Bioregulator Préclinique Non approuvé Russian bioregulator; small preclinical/cell-culture studies only.
Chonluten Bioregulator Préclinique Non approuvé Khavinson respiratory tripeptide (supplement); preclinical/in-vitro only.
LL-37 (KR-12) KR-12 Immune Préclinique Non approuvé Minimal antimicrobial fragment studied in vitro/animal only.
Cardiogen Bioregulator Préclinique Non approuvé Khavinson cardiac bioregulator (supplement); preclinical only.
Bronchogen Bioregulator Préclinique Non approuvé Khavinson bioregulator (supplement); Russian preclinical/in-vitro only.
Pancragen Bioregulator Préclinique Non approuvé Khavinson tetrapeptide studied in animal/primate/in-vitro; no rigorous human trials.
ZP-3022 GLP-1 / Metabolic Préclinique Non approuvé GLP-1/gastrin dual agonist studied in db/db mice & ZDF rats; no human trials.
SERP-2 Immune Préclinique Non approuvé Myxoma-virus serpin studied in rodent models / human cell lines in vitro.
AHK-Cu Acetyl Tripeptide Copper, AHK Copper Skin & Repair Préclinique Non approuvé —
Cartalax AED, Ala-Glu-Asp Bioregulator Préclinique Non approuvé —
Crystagen EDP, Glu-Asp-Pro Immune Préclinique Non approuvé —
Dermorphin Other Préclinique Non approuvé —
GDF-8 Myostatin Growth Factor Préclinique Non approuvé —
Orexin A Hypocretin-1 Sleep Préclinique Non approuvé —
Orexin B Hypocretin-2 Sleep Préclinique Non approuvé —
PE-22-28 Spadin analog Cognitive Préclinique Non approuvé —
Lipo-C Metabolic Pas encore de preuves Non approuvé Compounded MIC (methionine-inositol-choline) mix; no controlled efficacy studies of the formulation.

Le statut d'approbation reflète les registres réglementaires publics lors de la dernière révision et peut changer. L'inclusion est informative, pas une recommandation ; la plupart des composés sont réservés à la recherche en laboratoire et non approuvés pour l'usage humain.